Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. reports financial results and operating updates for a consumer wellness business focused on hemp extracts, CBD products and natural wellness ingredients. News commonly covers revenue trends, gross margin, operating expense reductions, adjusted EBITDA, cash flow objectives and balance-sheet actions such as secured note amendments and convertible debt features.
Company updates also include product launches across +PlusCBD, +PlusHLTH, Ignite and Empowr, including CBD gummies, pet products, cannabinoid-free supplements and plant-based nutrition formulas. Recurring coverage also addresses the evolving regulatory environment for hemp-derived CBD and the company’s efforts to broaden its wellness product portfolio.
CV Sciences (OTCQB:CVSI) will announce its financial results for Q1 2021 on May 13, 2021, after market close. A conference call to discuss these results is scheduled for 1:30 PM PT (4:30 PM ET) on the same day. Access to the call will be available through the Company’s Investor Relations webpage, with a replay offered two hours post-call until May 20, 2021. CV Sciences operates in two sectors: consumer products and drug development, with its PlusCBD™ products leading the hemp-derived CBD market across over 7,300 retail locations in the U.S.
CV Sciences (OTCQB: CVSI) has announced a partnership with Alkemist Labs to support the National Institute of Standards and Technology (NIST) in enhancing cannabis testing methodologies. This collaboration aims to improve measurement accuracy for cannabis products, crucial for legal and safety claims. CV Sciences will provide hemp oil samples for testing, and Alkemist Labs will measure cannabinoid levels. NIST’s Canna Quality Assurance Program (CannaQAP) will benefit various laboratories and researchers in the cannabis industry.
CV Sciences reported financial results for the year ended December 31, 2020, with revenues of $24.4 million, a 55% decline from $53.7 million in 2019. The gross margin stood at 45.1%, while the cash balance remained stable at $4.5 million. The company expanded its retail distribution to over 7,300 stores, up from 5,500 the previous year. Despite these advancements, an operating loss of $22.6 million was reported, marking an increase from $17.2 million in 2019, and a negative adjusted EBITDA of $11.6 million.
CV Sciences, Inc. (OTCQB:CVSI) will release its financial results for the fiscal year and fourth quarter ending December 31, 2020, on March 18, 2021. The company will conduct a conference call on the same day at 1:30 p.m. PT, which can be accessed via the Investor Relations section of its website. The PlusCBD™ brand leads the hemp-derived CBD market in over 7,300 retail locations and is compliant with Good Manufacturing Practices (GMP). The company emphasizes its commitment to scientific research in support of its products.
CV Sciences has announced a major refresh of its PlusCBD™ product line, introducing over 30 new products in the next 45 days. The updated line features contemporary packaging and innovative products such as extra strength gummies and softgels. Each product now includes a QR code linking to lab reports, ensuring quality assurance. According to CEO Joseph Dowling, extensive market research led to this redesign aimed at broadening consumer appeal and reinforcing brand equity. PlusCBD™ remains the top-selling CBD brand, derived from sustainable U.S. and EU hemp.